Evaluation of DNA intercalation potential of pharmaceuticals and other chemicals by cell‐based and three‐dimensional computational approaches

To what extent noncovalent chemical‐DNA interactions, in particular weak nonbonded DNA intercalation, contribute to genotoxic responses in mammalian cells has not been fully elucidated. Moreover, with the exception of predominantly flat, multiple‐fused‐ring structures, our ability to predict intercalation ability of novel compounds is nearly completely lacking. Computational programs such as DEREK and MCASE recognize primarily those molecules that can form irreversible covalent adducts with DNA since their learning sets, for the most part, have not been populated by compounds for which a relationship between noncovalent interaction and genotoxicity exists. We describe here a novel three‐dimensional (3D) computational DNA‐docking model for prediction of DNA intercalative activity of molecules with both classical and nonclassical intercalating structures. The 3D docking results show a remarkable concordance with results obtained from testing these molecules directly in the Chinese hamster V79 cell‐based bleomycin amplification system suggesting that either or both of these approaches may have utility in defining noncovalent chemical‐DNA interactions. The ability to predict and/or demonstrate cellular DNA intercalation of novel molecules may well provide fresh insights into the nature and mechanistic basis of structurally unexpected genotoxicity observed during safety testing. Environ. Mol. Mutagen. 44:163–173, 2004. © 2004 Wiley‐Liss, Inc.

[1]  R. Snyder,et al.  Assessment of the sensitivity of the computational programs DEREK, TOPKAT, and MCASE in the prediction of the genotoxicity of pharmaceutical molecules , 2004, Environmental and molecular mutagenesis.

[2]  R. Snyder Evidence from Studies with Intact Mammalian Cells That Merbarone and bis(Dioxopiperazine)s Are Topoisomerase II Poisons , 2003, Drug and chemical toxicology.

[3]  Neal F. Cariello,et al.  Comparison of the computer programs DEREK and TOPKAT to predict bacterial mutagenicity. Deductive Estimate of Risk from Existing Knowledge. Toxicity Prediction by Komputer Assisted Technology. , 2002, Mutagenesis.

[4]  Ronald D Snyder,et al.  Putative identification of functional interactions between DNA intercalating agents and topoisomerase II using the V79 in vitro micronucleus assay. , 2002, Mutation research.

[5]  Nigel Greene,et al.  Computer systems for the prediction of toxicity: an update. , 2002, Advanced drug delivery reviews.

[6]  R. Snyder,et al.  EVIDENCE FOR AND ROLE OF THE DIMETHYLAMINO GROUP IN TAMOXIFEN DNA INTERCALATION IN INTACT CHINESE HAMSTER V79 CELLS , 2002, Drug and chemical toxicology.

[7]  Ronald D Snyder,et al.  Evaluation of the clastogenic, DNA intercalative, and topoisomerase II‐interactive properties of bioflavonoids in Chinese hamster V79 cells , 2002, Environmental and molecular mutagenesis.

[8]  E. D. Bransome,et al.  Gene based pharmacophores for drug design , 2001 .

[9]  T. Halgren,et al.  Polarizable force fields. , 2001, Current opinion in structural biology.

[10]  R. Snyder,et al.  The bleomycin amplification assay in V79 cells predicts frameshift mutagenicity of intercalative agents. , 2000, Mutagenesis.

[11]  R. Snyder,et al.  Use of catalytic topoisomerase II inhibitors to probe mechanisms of chemical‐induced clastogenicity in Chinese hamster V79 cells , 2000, Environmental and molecular mutagenesis.

[12]  V. Mahesh,et al.  Multidimensional screening and design of pharmaceuticals by using endocrine pharmacophores , 1999, Steroids.

[13]  L. Strekowski,,et al.  Enhancement of bleomycin-induced micronucleus formation in V79 cells as a rapid and sensitive screen for non-covalent DNA-binding compounds. , 1999, Mutation research.

[14]  R. Snyder A review and investigation into the mechanistic basis of the genotoxicity of antihistamines. , 1998, Mutation research.

[15]  G. Capranico,et al.  DNA sequence selectivity of topoisomerases and topoisomerase poisons. , 1998, Biochimica et biophysica acta.

[16]  E. D. Bransome,et al.  The ligand insertion hypothesis in the genomic action of steroid hormones 1 1 Proceedings of the 13th International Symposium of the Journal of Steroid Biochemistry & Molecular Biology “Recent Advances in Steroid Biochemistry & Molecular Biology” Monaco 25–28 May 1997. , 1998, The Journal of Steroid Biochemistry and Molecular Biology.

[17]  L. Hendry,et al.  Impact of Pcbs On Thyroid Hormone Directed Brain Development , 1998, Toxicology and industrial health.

[18]  J. Copland,et al.  Design of novel antiestrogens , 1994, The Journal of Steroid Biochemistry and Molecular Biology.

[19]  L. Strekowski,,et al.  Quantitative structure-activity relationship analysis of cation-substituted polyaromatic compounds as potentiators (amplifiers) of bleomycin-mediated degradation of DNA. , 1991, Journal of medicinal chemistry.

[20]  L. Hendry Stereochemical complementarity of DNA and steroid agonists and antagonists , 1988 .

[21]  A. Lehner,et al.  Initial studies of a phytoestrogen-deoxyribonucleic acid interaction. , 1987, Molecular endocrinology.

[22]  E. D. Bransome,et al.  Structure — activity relationships of some unique estrogens related to estradiol are predicted by fit into dna , 1985, Steroids.

[23]  M. Fenech,et al.  Measurement of micronuclei in lymphocytes. , 1985, Mutation research.

[24]  J. F. Becker,et al.  Characterization of reversible, physical binding of benzo[a]pyrene derivatives to DNA. , 1982, The Journal of biological chemistry.

[25]  L. Hendry,et al.  Gene Regulation: The Involvement of Stereochemical Recognition in DNA-Small Molecule Interactions , 2015, Perspectives in biology and medicine.